New cell therapy shows promise for Hard-to-Treat blood cancer
Disease control
Completed
This early-stage trial tested a new cell therapy called FT576, given alone or with another drug (daratumumab), in 31 people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find safe doses and check for side effects. The st…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:39 UTC